ABIO Insider Trading (ARCA biopharma)
Insider Ownership Percentage: 0.48%
Insider Buying (Last 12 Months): $1,205,974.29
Insider Selling (Last 12 Months): $0.00
ARCA biopharma Share Price & Price History
Current Price: $2.47
Price Change: ▼ Price Decrease of -0.03 (-1.20%)
As of 06/30/2022 01:01 PM ET
Former Lawyer Went From $50K To $5.3M Trading Options
From Investing Daily | Ad
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.
I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).
I grew my $50K into $5.3M
I'll show you how I did it here.
ARCA biopharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/25/2022 | Fund Lp Funicular | Insider | Buy | 64,851 | $2.32 | $150,454.32 | 2,580,452 |  |
| 5/23/2022 | Fund Lp Funicular | Insider | Buy | 2,301 | $2.29 | $5,269.29 | 2,497,491 | |
| 5/18/2022 | Fund Lp Funicular | Insider | Buy | 13,072 | $2.30 | $30,065.60 | 2,495,189 | |
| 5/16/2022 | Fund Lp Funicular | Insider | Buy | 42,914 | $2.30 | $98,702.20 | 2,482,117 | |
| 5/13/2022 | Fund Lp Funicular | Insider | Buy | 14,000 | $2.29 | $32,060.00 | 2,439,203 | |
| 5/11/2022 | Fund Lp Funicular | Insider | Buy | 24,596 | $2.29 | $56,324.84 | 2,397,281 | |
| 5/9/2022 | Fund Lp Funicular | Insider | Buy | 49,221 | $2.27 | $111,731.67 | 2,351,706 | |
| 5/5/2022 | Fund Lp Funicular | Insider | Buy | 16,903 | $2.27 | $38,369.81 | 2,244,487 | |
| 5/2/2022 | Fund Lp Funicular | Insider | Buy | 1,259 | $2.31 | $2,908.29 | 2,227,584 | |
| 4/28/2022 | Fund Lp Funicular | Insider | Buy | 23,381 | $2.32 | $54,243.92 | 2,217,351 | |
| 4/25/2022 | Fund Lp Funicular | Insider | Buy | 13,751 | $2.29 | $31,489.79 | 2,193,970 | |
| 4/18/2022 | Fund Lp Funicular | Insider | Buy | 9,119 | $2.31 | $21,064.89 | 2,180,219 | |
| 4/14/2022 | Fund Lp Funicular | Insider | Buy | 17,410 | $2.33 | $40,565.30 | 2,171,100 | |
| 4/11/2022 | Fund Lp Funicular | Insider | Buy | 4,655 | $2.31 | $10,753.05 | 2,084,292 | |
| 4/8/2022 | Fund Lp Funicular | Insider | Buy | 30,660 | $2.31 | $70,824.60 | 2,079,637 | |
| 4/6/2022 | Fund Lp Funicular | Insider | Buy | 26,806 | $2.30 | $61,653.80 | | |
| 4/4/2022 | Fund Lp Funicular | Insider | Buy | 122,342 | $2.26 | $276,492.92 | 2,048,977 | |
| 11/22/2021 | Christopher David Ozeroff | VP | Buy | 50,000 | $2.26 | $113,000.00 | | |
| 5/12/2021 | Robert E Conway | Chairman | Buy | 10,000 | $3.19 | $31,900.00 | 50,000 | |
| 5/5/2021 | Robert E Conway | Chairman | Buy | 10,000 | $3.23 | $32,300.00 | 40,000 | |
| 12/18/2020 | Robert E Conway | Chairman | Buy | 10,000 | $4.16 | $41,600.00 | 30,000 | |
| 9/25/2020 | Robert E Conway | Chairman | Buy | 5,000 | $4.28 | $21,400.00 | 20,000 | |
| 9/21/2020 | Robert E Conway | Chairman | Buy | 10,000 | $4.77 | $47,700.00 | 11,944 | |
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
ARCA biopharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/17/2022 | Virtu Financial LLC | 23,874 | $55K | 0.0% | N/A | 0.166% |  |
| 5/13/2022 | Vanguard Group Inc. | 459,562 | $1.06M | 0.0% | +13.1% | 3.189% | |
| 4/26/2022 | Marquette Asset Management LLC | 17,318 | $40K | 0.0% | N/A | 0.120% | |
| 2/10/2022 | Acadian Asset Management LLC | 57,822 | $0.12M | 0.0% | N/A | 0.401% | |
| 11/15/2021 | GSA Capital Partners LLP | 441,945 | $1.31M | 0.1% | +238.9% | 3.067% | |
| 11/15/2021 | Minerva Advisors LLC | 10,000 | $30K | 0.0% | N/A | 0.069% | |
| 11/9/2021 | BlackRock Inc. | 268,394 | $0.80M | 0.0% | -1.8% | 1.863% | |
| 8/16/2021 | State Street Corp | 69,037 | $0.24M | 0.0% | N/A | 0.479% | |
| 8/13/2021 | Geode Capital Management LLC | 87,659 | $0.31M | 0.0% | +10.7% | 0.608% | |
| 8/13/2021 | Vanguard Group Inc. | 398,507 | $1.39M | 0.0% | +189.8% | 2.765% | |
| 8/12/2021 | XTX Topco Ltd | 10,846 | $38K | 0.0% | N/A | 0.075% | |
| 8/5/2021 | GSA Capital Partners LLP | 130,395 | $0.46M | 0.1% | +39.8% | 0.905% | |
| 5/19/2021 | Virtu Financial LLC | 16,655 | $61K | 0.0% | -32.4% | 0.116% | |
| 5/17/2021 | PDT Partners LLC | 17,297 | $63K | 0.0% | N/A | 0.120% | |
| 5/12/2021 | Geode Capital Management LLC | 79,151 | $0.29M | 0.0% | +141.7% | 0.549% | |
| 5/10/2021 | GSA Capital Partners LLP | 93,241 | $0.34M | 0.1% | +102.3% | 0.647% | |
| 2/24/2021 | Virtu Financial LLC | 24,641 | $99K | 0.0% | N/A | 0.264% | |
| 2/10/2021 | Renaissance Technologies LLC | 205,500 | $0.82M | 0.0% | +436.4% | 2.205% | |
| 2/10/2021 | Panagora Asset Management Inc. | 6,878 | $28K | 0.0% | N/A | 0.074% | |
| 2/4/2021 | GSA Capital Partners LLP | 46,097 | $0.19M | 0.0% | N/A | 0.495% | |
| 11/19/2020 | Schonfeld Strategic Advisors LLC | 18,200 | $80K | 0.0% | N/A | 0.195% | |
| 11/17/2020 | Schonfeld Strategic Advisors LLC | 18,200 | $80K | 0.0% | N/A | 0.195% | |
| 11/6/2020 | BlackRock Inc. | 287,263 | $1.27M | 0.0% | +598,364.6% | 4.865% | |
| 8/13/2020 | Tekla Capital Management LLC | 32,461 | $0.22M | 0.0% | -10.0% | 0.550% | |
| 5/11/2020 | Acadian Asset Management LLC | 28,423 | $80K | 0.0% | +64.0% | 1.788% | |
| 2/13/2020 | Renaissance Technologies LLC | 142,572 | $0.81M | 0.0% | +42.4% | 8.944% | |
| 8/12/2019 | Renaissance Technologies LLC | 80,485 | $0.59M | 0.0% | -91.1% | 5.528% | |
| 8/12/2019 | Quantamental Technologies LLC | 5,148 | $38K | 0.0% | N/A | 0.353% | |
| 8/8/2019 | Acadian Asset Management LLC | 17,333 | $0.13M | 0.0% | -92.1% | 1.187% | |
| 8/6/2019 | Aveo Capital Partners LLC | 95,715 | $0.66M | 0.3% | +2.6% | 6.574% | |
| 11/13/2018 | Renaissance Technologies LLC | 670,459 | $0.38M | 0.0% | +59.9% | 4.817% | |
| 11/13/2018 | Virtu Financial LLC | 176,131 | $0.54M | 0.0% | +416.1% | 1.265% | |
| 8/13/2018 | Renaissance Technologies LLC | 419,250 | $0.23M | 0.0% | -21.4% | 3.012% | |
| 2/13/2018 | Renaissance Technologies LLC | 129,705 | $0.18M | 0.0% | -45.2% | 1.104% | |
| 2/9/2018 | Royce & Associates LP | 324,847 | $0.45M | 0.0% | +38.3% | 2.765% | |
| 11/14/2017 | Royce & Associates LP | 234,847 | $0.26M | 0.0% | +30.6% | 1.999% | |
| 8/14/2017 | Tekla Capital Management LLC | 811,227 | $1.99M | 0.1% | No Change | 6.904% | |
| 8/10/2017 | Franklin Resources Inc. | 1,216,840 | $2.98M | 0.0% | No Change | 13.166% | |
| 8/7/2017 | Royce & Associates LP | 179,847 | $0.44M | 0.0% | +476.4% | 1.946% | |
| 8/1/2017 | Aveo Capital Partners LLC | 93,667 | $0.23M | 0.1% | +93.7% | 1.013% | |
| 7/26/2017 | NEA Management Company LLC | 1,460,209 | $3.51M | 0.1% | No Change | 15.800% | |
Data available starting January 2016
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Read More on ARCA biopharma
Volume
500 shs
Average Volume
127,347 shs
Market Capitalization
$35.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.2
Who are the company insiders with the largest holdings of ARCA biopharma?
